fatnews.com

SEARCH

Wednesday, October 17, 2018

PCSK9 INHIBITORS

4% more people given PCSK9 inhibitor evolocumab (Repatha) died during 2.2 years (444 vs 426 deaths)

4% more people given the PCSK9 inhibitor evolocumab (Repatha) to lower cholesterol levels died during an average follow-up of 2.2 years than those given a placebo according to the FOURIER trial.

444 people (out of 13,784) given evolocumab died compared to 426 people (out of 13,780) given a placebo.

So they want me to take a drug that you have to inject that costs $14,000 per year that increases my chance of dying?

No, thank you.

Read the entire article | Email this article
Posted by Larry Hobbs on Wed, Oct 17, 2018 12:37 pm | [0] comments
Follow @fatnews

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • QUOTE OF THE DAY

    Books by Larry Hobbs available on Amazon

    Book cover for The Case Against Statins

    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.